ArticleDrug and alcohol dependence2021
Use of highly-potent cannabis concentrate products: More common in U.S. states with recreational or medical cannabis laws.
Article in Drug and alcohol dependence, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Association between state cannabis laws and opioid outcomes: A systematic review.Drug and alcohol dependence · 2026Pooled it
- High-Potency Cannabis Use and Health: A Systematic Review of Observational and Experimental Studies.The American journal of psychiatry · 2025Pooled it
- The role of subcortical brain tissue iron as an indicator of dopamine neurophysiology in adolescent cannabis use.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Cannabis use patterns and perception of acute pain during brief abstinence: sex-dependent associations with circulating cannabinoid levels.Psychopharmacology · 2026Article
- Content Analysis of Derived Intoxicating Cannabis Vape Product Attributes and Marketing In an Online Retail Environment.Substance use & misuse · 2026Article
- Racial and Ethnic Differences in Suicide Mortality Among Youth Aged 12-25 Years Following Medical and Recreational Cannabis Legalization in the U.S.American journal of preventive medicine · 2026Article
- Centering Individuals With Mental Illness as an At-Risk Group in the Era of Cannabis Legalization and Commercialization.Clinical therapeutics · 2026Article
- U.S. State Marijuana and Delta-8-Tetrahydrocannabinol Laws and Delta-8-Tetrahydrocannabinol Use.American journal of preventive medicine · 2025Article
- Associations between recreational cannabis legalization and cannabis use disorder treatment outcomes in California, 2010-2021.Journal of cannabis research · 2025Article
- Patterns of Cannabis Use among Women With HIV in the United States.AIDS and behavior · 2025Article
- The Combined Relationship of Prescription Drug Monitoring Program Enactment and Medical Cannabis Laws with Chronic Pain-Related Healthcare Visits.Journal of general internal medicine · 2025Article
- Quantity of delta-9-tetrahydrocannabinol consumption and cannabis use disorder among daily cannabis consumers.Addiction (Abingdon, England) · 2025Article
- Multi-Modal Cannabis Use Among U.S. Young Adults: Findings from the 2022 and 2023 BRFSS in 23 States.International journal of environmental research and public health · 2025Article
- Extending Gender- and Sex-Based Analyses in Cannabis Research: Findings from an Online Sample of Gender Diverse Young Adult Consumers.Cannabis and cannabinoid research · 2024Article
- Associations between Cannabis Consumption Methods and Cannabis Risk Perception.International journal of environmental research and public health · 2024Article
- Germany's cannabis act: a catalyst for European drug policy reform?The Lancet regional health. Europe · 2024Review
- Typical Hits, Grams, or Joints: Evaluating Cannabis Survey Measurement Strategies for Quantifying Consumption.Cannabis and cannabinoid research · 2024Article
- Self-reported knowledge of tetrahydrocannabinol and cannabidiol concentration in cannabis products among cancer patients and survivors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Association Between Marijuana Laws and Suicide Among 12- to 25-Year-Olds in the United States From 2000 to 2019.Journal of the American Academy of Child and Adolescent Psychiatry · 2024Article
- ΔCannabis and cannabinoid research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundHighly-potent cannabis products, e.g., concentrates, entail greater risks of cannabis-related harms than lower-potency products such as plant or flower material. However, little information is available on whether individuals in U.S. states with recreational cannabis laws (RCL) or medical cannabis laws (MCL) are more likely than individuals in U.S. states without cannabis legalization (no-CL) to use highly-potent forms of cannabis.
methodsCannabis-using adults in a 2017 online survey (N = 4064) provided information on state of residence and past-month cannabis use, including types of products used, categorized as low-potency (smoked or vaped plant cannabis) or high-potency (vaping or dabbing concentrates). Multivariable logistic regression models generated adjusted odds ratios (aOR) and 95% confidence intervals (CI) for use of high-potency cannabis products by state cannabis legalization status (RCL, MCL, no-CL).
resultsCompared to participants in no-CL states, participants in RCL states had greater odds of using high-potency concentrate products (aOR=2.61;CI=1.77-3.86), as did participants in MCL-only states (aOR=1.55;CI=1.21-1.97). When participants in RCL states and MCL states were directly compared, those in RCL states had greater odds of using high-potency concentrate products (aOR=1.69;CI=1.27-2.42). DISCUSSION: Although the sample was not nationally representative and the cross-sectional data precluded determining the direction of effect, results suggest that use of high-potency cannabis concentrates is more likely among those in RCL states. Clinicians in RCL states should screen cannabis users for harmful patterns of use. Policymakers in states that do not yet have RCL should consider these findings when drafting new cannabis laws, including the specific products permitted and how best to regulate them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.